LUNG CANCER

Latest News

November 13th 2015

Dr. Geoffrey R. Oxnard on When to Change EGFR TKIs

Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, talks about the treatment options for patients with lung cancer who have become resistant to their first-line treatments.

November 13th 2015

Osimertinib Approved by FDA for EGFR T790M-Positive NSCLC

By Silas Inman

November 7th 2015

Molecular Targeting in Non-Small Cell Lung Cancer

By Greg Kennelty

November 7th 2015

Checkpoint Inhibitors Promising for SCLC, Mesothelioma

By Silas Inman

November 4th 2015

Dr. Gregory Riely on Potential Treatment for Patients With MET Exon 14 Mutation

By Gregory J. Riely, MD, PhD

Latest Videos

Results for Durvalumab in the Second-Line Treatment of NSCLC

Nivolumab With Ipilimumab for Small Cell Lung Cancer

Impact of MET Inhibitors in MET Exon 14-Mutant NSCLC

First-Line Carboplatin and Pemetrexed With Pembrolizumab for NSCLC

Phase III Results for Alectinib Compared With Crizotinib in ALK+ Metastatic NSCLC

Treatment of EGFR Mutant Non-Small Cell Lung Cancer

Treatment Options at Relapse for EGFR-Mutated NSCLC

Factors to Consider in Treating EGFR-Mutant NSCLC

Molecular Testing for NSCLC

A Case of EGFR-Mutant NSCLC

CME Content

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Rocky Mountain Oncology Society

Seth A. Wander, MD, PhD; Kara M. Schenk, MD

Video

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | North Carolina Oncology Association

Marla D. Lipsyc-Sharf, MD; Yan Ji, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Kimberly Ku, MD

Video

43rd Annual Miami Breast Cancer Conference®

Patrick I. Borgen, MD; Reshma Jagsi, MD, DPhil; Hope S. Rugo, MD, FASCO

Multimedia

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

Multimedia

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

Multimedia

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Multimedia

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

Multimedia

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

In-Person Event

Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics, and Beyond

May 22, 2026

Register now!

Multimedia

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Video

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

More News

The Evolving Landscape of Lung Cancer Treatment Over the Last 10 Years

ByGreg Kennelty

November 4th 2015

From just chemotherapy to molecular and immune focused therapies, the landscape of non-small cell lung cancer (NSCLC) has drastically changed over the course of the last 10 years according to Heather Wakelee, MD.

LUNG CANCER

Latest News

Latest Videos

Results for Durvalumab in the Second-Line Treatment of NSCLC

Nivolumab With Ipilimumab for Small Cell Lung Cancer

Impact of MET Inhibitors in MET Exon 14-Mutant NSCLC

First-Line Carboplatin and Pemetrexed With Pembrolizumab for NSCLC

Phase III Results for Alectinib Compared With Crizotinib in ALK+ Metastatic NSCLC

Treatment of EGFR Mutant Non-Small Cell Lung Cancer

Treatment Options at Relapse for EGFR-Mutated NSCLC

Factors to Consider in Treating EGFR-Mutant NSCLC

Molecular Testing for NSCLC

A Case of EGFR-Mutant NSCLC

CME Content

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Rocky Mountain Oncology Society

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | North Carolina Oncology Association

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

43rd Annual Miami Breast Cancer Conference®

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics, and Beyond

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

24th Annual International Congress on the Future of Breast Cancer® East

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

More News

The Evolving Landscape of Lung Cancer Treatment Over the Last 10 Years

Metastatic NSCLC with Corey J. Langer, MD, David Spigel, MD, Denise O'Dea, NP, and Jack West, MD: Case 2

Jack West, MD: Options for Treatment and Reimbursement

Jack West, MD: Maintaining Current Dosage and Getting Adequate Nursing and Support

Jack West, MD: Managing Adverse Events Such as Rash and Stomatitis

Jack West, MD: Concern About Potential Drug Interactions

Jack West, MD: Use of TKI Therapy in Patients with EGRF Exon 21 Substitutions (L858R)

Denise O'Dea, NP: Options for Treatment and Reimbursement

Denise O'Dea, NP: Maintaining Current Dosage and Getting Adequate Nursing and Support

Denise O'Dea, NP: Managing Adverse Events Such as Rash and Stomatitis

Denise O'Dea, NP: Concern About Potential Drug Interactions

Denise O'Dea, NP: Use of TKI Therapy in Patients with EGRF Exon 21 Substitutions (L858R)

Corey J. Langer, MD: Options for Treatment and Reimbursement

Corey J. Langer, MD: Maintaining Current Dosage and Getting Adequate Nursing and Support

Corey J. Langer, MD: Managing Adverse Events Such as Rash and Stomatitis

Corey J. Langer, MD: Concern About Potential Drug Interactions

Corey J. Langer, MD: Use of TKI Therapy in Patients with EGRF Exon 21 Substitutions (L858R)

David Spigel, MD: Options for Treatment and Reimbursement

David Spigel, MD: Maintaining Current Dosage and Getting Adequate Nursing and Support

David Spigel, MD: Managing Adverse Events Such as Rash and Stomatitis

David Spigel, MD: Concern About Potential Drug Interactions

David Spigel, MD: Use of TKI Therapy in Patients with EGRF Exon 21 Substitutions (L858R)

Metastatic NSCLC with Corey J. Langer, MD, David Spigel, MD, Denise O'Dea, NP, and Jack West, MD: Case 1

Jack West, MD: Options for Treatment and Reimbursement After Dose Reduction

Jack West, MD: Concern About Drug Interactions